Vimarsana
Biggest News Aggregation in the World

Page 2 - Subgroup Analyses News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Subgroup Analyses. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Subgroup Analyses Today - Breaking & Trending Today

Effect of Repeated Low-level Red Light on Myopia Prevention Among Children in China With Premyopia: A Randomized Clinical Trial | Ophthalmology | JAMA Network Open - Vimarsana News

Effect of Repeated Low-level Red Light on Myopia Prevention Among Children in China With Premyopia: A Randomized Clinical Trial | Ophthalmology | JAMA Network Open

This randomized clinical trial assesses the efficacy and safety of a repeated low-level red-light intervention in preventing incident myopia among children in C

Guidelines for Reporting Outcomes in Trial Reports - Vimarsana News

Guidelines for Reporting Outcomes in Trial Reports

This report, the Consolidated Standards of Reporting Trials (CONSORT)–Outcomes 2022 extension, is a consensus statement on the standards for reporting outcomes

Guidelines for Reporting Outcomes in Trial Protocols - Vimarsana News

Guidelines for Reporting Outcomes in Trial Protocols

This report, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)–Outcomes 2022 extension, is a consensus statement on the standards

Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial | Oncology | JAMA - Vimarsana News

Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial | Oncology | JAMA

This randomized clinical trial assesses the effect of using weekly electronic patient-reported outcome surveys to monitor symptoms, compared with usual care, on

Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA - Vimarsana News

Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA

Longer term follow-up data will be presented from the pivotal CARTITUDE-1 study in patients with relapsed or refractory multiple myeloma, which supported the recent U.S. FDA approval of CARVYKTI